Nuvalent
Signal active
Organization
Contact Information
Overview
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
About
Industries
Biotechnology, Life Science, Therapeutics
Founded
2017
Employees
51-100
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Nuvalent headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $36.0B in funding across 48 round(s). With a team of 51-100 employees, Nuvalent is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Nuvalent, raised $300.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
0
Lead Investors
0
Total Funding Amount
$749.5M
Details
2
Nuvalent has raised a total of $749.5M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 50.0M | ||
| 2021 | Early Stage Venture | 135.0M |
Investors
Nuvalent is funded by 17 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Nuvalent | - | FUNDING ROUND - Nuvalent | 135.0M |
| Bain Capital Life Sciences | - | FUNDING ROUND - Bain Capital Life Sciences | 135.0M |
| Nuvalent | - | FUNDING ROUND - Nuvalent | 135.0M |
| Wellington Management | - | FUNDING ROUND - Wellington Management | 135.0M |
Recent Activity
There is no recent news or activity for this profile.